leadf
logo-loader
viewCytoDyn Inc.

CytoDyn reveals latest mild-to-moderate coronavirus patient data in Phase 2 trial

CytoDyn Inc (OTCQB:CYDY) CEO Nader Pourhassan says its drug leronlimab showed early clinical improvement in mild-to-moderate coronavirus patients in a recently completed Phase 2 trial.

Pourhassan says in patients with a Total Clinical Symptom Score of 4 or more, with higher scores indicating a worse health state, leronlimab led to a greater improvement after three days (90% of patient scores improved) than the placebo (71% of scores improved).

Quick facts: CytoDyn Inc.

Price: 3.06 USD

OTCQB:CYDY
Market: OTCQB
Market Cap: $1.85 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

CytoDyn achieves 75% enrollment for its severe-to-critical coronavirus...

CytoDyn Inc (OTCQB:CYDY) CEO Nader Pourhassan tells Proactive the biotechnology company has achieved the enrollment of 293 patients with severe-to-critical coronavirus symptoms, meeting the criteria for a second interim analysis by the Data Safety Monitoring Committee (DSMC). Pourhassan says...

on 11/23/2020

2 min read